Sanofi SA (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 224   

Articles published

SNY 49.97 +1.17 (2.40%)
price chart
Amgen, Inc., Sanofi SA (ADR)-Regeneron Pharmaceuticals Inc PCSK9 Inhibitors ...
The research, collected from considerably smaller studies sponsored separately by Amgen, Inc. (NASDAQ:AMGN) and Sanofi SA (ADR) (NYSE:SNY) as well as its partner Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), was presented at the annual ...
Sanofi SA (SNY) Q4 Earnings Preview
Sanofi SA (ADR) (NYSE:SNY) is scheduled to announce its financial results for the fourth quarter of fiscal year 2014 (4QFY14) on Thursday, February 5 before the market opens.
Sanofi SA (ADR) (SNY) Upgraded To Outperform By Leerink Partners
Sanofi SA (ADR) (NYSE:SNY) stock was upgraded from a Market Perform rating to an Outperform rating by analysts at Leerink Swann & Company in a research report issued to clients on Tuesday.
Leerink Swann & Company promoted Sanofi SA (ADR) (NYSE:SNY) to an Outplay  Stocks.org
5 Active Stocks: Sanofi SA (ADR) (NYSE:SNY), OPOWER (NYSE:OPWR ...  Gaining Green
Zacks Long Term Rating Update on Sanofi SA (ADR)
As much as 5 analysts have advised buy on Sanofi SA (ADR) (NYSE:SNY) with an average broker rating of 2.2. Zacks research analysts are highly pessimistic on the counter and has given it a short term rating of 5, indicating that it is a Underperform ...
Company Shares of Sanofi SA (ADR) Rally 1.38%  Ashburn Daily
Price Target Update on Sanofi SA (ADR)
Sanofi SA (ADR) (NYSE:SNY): The mean estimate for the short term price target for Sanofi SA (ADR) (NYSE:SNY) stands at $55 according to 2 Analysts.
Analyst Rating Update on Sanofi SA (ADR)  Ashburn Daily
Sanofi Fires CEO Following Clash With Board
Sanofi SA (ADR) (SNY) announced today that the company's board has decided to oust Chief Executive Officer Christopher Viehbacher, finally putting the rumors to rest.
Related articles »  
Whistleblower Lawsuit Accuses Sanofi SA (SNY), Ousted CEO Of Kickback ...
Sanofi SA (ADR) (NYSE:SNY) has found itself caught in a whistleblower lawsuit, where a former employee is accusing the company of funneling $34 million in kickbacks and incentive payments to various doctors and pharmacies, influencing them to prescribe ...
Related articles »  
Sanofi SA (SNY) Pipeline Deserves More Credit, Says Citi
Citi, which has a price target of �79 on Sanofi stock, also highlighted the overhang from potential delays of Sanofi-Regeneron's cholesterol drug Praluent due to litigation issues with Amgen, Inc. (NASDAQ:AMGN). Amgen has sued the duo for infringing on ...
AbbVie Inc (ABBV), Celgene Corporation (CELG), Sanofi SA (ADR) (SNY ...  StockWise Daily
Related articles »  
Sanofi SA (ADR) (SNY) And Netflix, Inc. (NFLX) Executives Entangled In ...
When Sanofi SA (ADR) (NYSE:SNY) CEO Christopher Viehbacher was sacked recently, it was believed that the disagreement between him and the board was the reason of his unfortunate exit.
Has Sanofi SA (ADR) (NYSE:SNY) Fallen Enough?
Sanofi's diabetes franchise appears to be in trouble, with its drug Lantus facing increased competition. The company has projected flat sales for its diabetes offerings, in great part due to increased generic competition when Lantus loses its patent ...
Despite Myriad Of Issues, Sanofi Might Be A Good Buy  Seeking Alpha